Get the Stockscreener App
1.625
0.31%
-0.005
Pre-market:
1.62
-0.005
-0.31%
Lava Therapeutics Nv stock is traded at $1.625, with a volume of 14,875.
It is down -0.31% in the last 24 hours and up +4.17% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.63
Open:
$1.6
24h Volume:
14,875
Relative Volume:
0.04
Market Cap:
$42.75M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
-1.5435
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
+0.93%
1M Performance:
+4.17%
6M Performance:
+30.00%
1Y Performance:
-10.22%
1-Day Range:
$1.5812
$1.63
1-Week Range:
$1.58
$1.64
52-Week Range:
$0.8502
$2.00
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.625 | 42.88M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Ranking LAVA Therapeutics N.V. among high performing stocks via tools2025 Key Highlights & Stepwise Swing Trade Plans - newser.com
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsJuly 2025 Earnings & Daily Risk Controlled Trade Plans - newser.com
Is LAVA Therapeutics N.V. showing signs of accumulationEarnings Summary Report & Consistent Income Trade Recommendations - newser.com
How to track smart money flows in LAVA Therapeutics N.V.Chart Signals & Stock Timing and Entry Methods - newser.com
How LAVA Therapeutics N.V. stock valuations compare to rivalsPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
How analysts revise price targets for LAVA Therapeutics N.V. (4PKB) stock2025 Year in Review & Fast Exit and Entry Strategy Plans - newser.com
Analyzing LAVA Therapeutics N.V. with risk reward ratio chartsWeekly Stock Recap & Technical Buy Zone Confirmations - newser.com
Can LAVA Therapeutics N.V. hit a new high this monthTrade Performance Summary & Free Real-Time Market Sentiment Alerts - newser.com
Heatmap analysis for LAVA Therapeutics N.V. and competitorsBond Market & Daily Technical Forecast Reports - newser.com
Advanced analytics toolkit walkthrough for LAVA Therapeutics N.V.Market Growth Report & Stepwise Trade Signal Implementation - newser.com
Historical volatility pattern of LAVA Therapeutics N.V. visualizedWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Price momentum metrics for LAVA Therapeutics N.V. explained2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
Published on: 2025-10-31 00:32:41 - newser.com
Custom strategy builders for tracking LAVA Therapeutics N.V.Product Launch & Stepwise Entry/Exit Trade Alerts - newser.com
What analysts say about LAVA Therapeutics NV 4PKB stockInsider Trading Activity & Low Cost Portfolio Tips - earlytimes.in
What hedge fund activity signals for LAVA Therapeutics N.V. stockMarket Trend Report & AI Powered Buy/Sell Recommendations - fcp.pa.gov.br
Jobs Data: Why LAVA Therapeutics N.V. stock attracts global investors2025 Market Overview & Community Verified Swing Trade Signals - fcp.pa.gov.br
What indicators show strength in LAVA Therapeutics N.V.Market Sentiment Summary & Reliable Entry Point Alerts - newser.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lava Therapeutics Nv Stock (LVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 16 '25 |
Sale |
1.49 |
690,239 |
1,028,456 |
4,128,912 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 14 '25 |
Sale |
1.51 |
227,341 |
343,285 |
5,019,151 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 13 '25 |
Sale |
1.54 |
47,686 |
73,436 |
5,246,492 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 10 '25 |
Sale |
1.55 |
49,869 |
77,297 |
5,294,178 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):